# Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run

> **Open Intelligence Dossier** · First detected: 2026-10-09 03:20 UTC · Category: Business

## Executive Summary
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

## Intelligence Brief
&quot;Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run&quot; is generating significant coverage in the Business category, with 7 articles from 7 distinct sources tracked by PULSE so far.


Outlets currently covering the story include Fierce Pharma, WSJ, Investor&#039;s Business Daily and Reuters. PULSE measures a story&#039;s velocity from how quickly new articles appear and how many independent newsrooms join the coverage.


This brief was generated by PULSE&#039;s extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| Fierce Pharma | Argenx walks away from Vyvgart Sjögren's disease trial after futility flag | [Source Link](https://news.google.com/rss/articles/CBMipwFBVV95cUxQTGYxaDhPUHY3OS00LVJiaEM3YzlmeDF2LWpha05uUEFxS2V0SFdWV2NRbEZHWldkYUtkcmdiSnlGcklWUFFvRG8td0tDdHBJbU5wbnh1Rl9HYk5vS2VpQ0c2WUkzSWl4YUpKUnljUXpaX1g4QkNDRjFMbHBNZHhtTm1OQlZ1aGJBc243TjU4dDBSWjJab3VJbXJWNThNWmVZOUlFajkwSQ?oc=5) |
| WSJ | Argenx Shares Plunge After Autoimmune-Disease Trial Halt | [Source Link](https://news.google.com/rss/articles/CBMioAFBVV95cUxNcGdaSk93bDhwRXZpVkNkWm0xaFVHX1ZHeURtdDBkai14aVFscmtkTlFVcUNGTElGTGRraUItZFJrd3pfZ20wc0RSQlU5ekJDYTRUSDNibjBuVURvd29WNWdNTUExMzlWVVRjYVNRbWpFRXRJc1dHWlZlb3lIQTFVRWJ2cDM0REdSS1pHWlJSb1NacUpuMWdZZ0xfamF4Qmxz?oc=5) |
| Investor's Business Daily | Former Highflying Biotech Hits The Skids On A Surprise Failure | [Source Link](https://news.google.com/rss/articles/CBMihwFBVV95cUxQeUpIaVlRRUIyazhNY3M0b2h3bDM3a1JDVGhMdWhDN1ZsblZKaHA5M0t0TllPbVYyd3NDX1VuQWQ5a29SVldBZ3cwSlVDVHlfWmdjUzJRM3lUd2RnUU01X3lVdFlicjFJTWlYZXFuUTJjUjBwQkJXMEhnM3FjYk5LSmZrLXBNOVU?oc=5) |
| Reuters | Argenx discontinues Vyvgart study in Sjögren's disease, shares tumble | [Source Link](https://news.google.com/rss/articles/CBMitwFBVV95cUxOQ1VGX3BsbGNLQnZJRXBEeURjdmVpS2p0OVM2NDhpRnZMVElONjhQTnBuUHc1azFUdEJMN1JKc01IZTdiX0ZNME5sZmFYUVJVY0UtRWg5eTRyVHZBT182Z2h4LTNNOTd5cTVrWF9rTjBIVU5UWUVMWGxsZXJUVHE3XzV1WWlkYmpMUGo1MHc3WmpYc0Q4UEg0Ykl1eU5rbnRFNGZCZFlncmhGZHJicElPZXBJX3dJRVk?oc=5) |
| Yahoo Finance | Why Is ARGX Stock Plunging Today? | [Source Link](https://news.google.com/rss/articles/CBMimgFBVV95cUxQbE42LUxSY3FrTlBHSlZMVzRFR0V3bWZnd0EzUnlTMkFiay01MkN6QnZnbk1Qel9WRFoteFNBbWUtRFk3T1VhWnhHbmMwWlRRSmRVTXllWUgxV1FNQ2hBU1JWNFN5SFE2Rl9mSzVsX1NKZ1BjOUttSUZLRWlaWVhtYWVqS3NVcmpKVGt4MDNBRjF1dFcwMnFCamVB?oc=5) |
| STAT | Argenx sees unusual setback with failure of late-stage study of drug for autoimmune disease | [Source Link](https://news.google.com/rss/articles/CBMigwFBVV95cUxOdElDMHVUa0gzVThrS3lHYmNQZTB5V2x1RFJRR0tCbnR6R3BHVHNZOFcyT0dOcGlnb3hUQ0FWWS10bkNsLVlxQlNtQWp2N3NwZ0ZjSU1iUE9HWXlYeHJjVGh3VE5jcER6RnJ3a2lLMHBsT2tyYjB1R3BLeUxmUnJRRXpsbw?oc=5) |
| Fierce Biotech | Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run | [Source Link](https://news.google.com/rss/articles/CBMinwFBVV95cUxNWmJhclVnMm8yZHJUMkkxSnc1UmNIb1o0QlBteXRDR3hPa1ppRkNpWEI5YzFreE5yVlZlS1VFbjR1TXNnOGVxR1V6NFlycnRBZ1IwU0R3czhsRUMyOXl1WFhSQ0lPbk1xcFQ3U2lnWkozYzB0cWtUekpadUk5dEZHWTZqN2o2U3hja3UwVU1JWnlCZi1JN2RWWGttc1pPQ1k?oc=5) |

---
*Canonical Source: https://pulse.byoaiapps.com/trend/2026-10-09/argenx-digests-phase-2-celiac-win-for-2-2b-drug-preps-pivotal-run*
